Antithrombin iii human
Antithrombin iii human is an unknown pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| thrombate iii | Biologic Licensing Application | 2010-01-10 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
4852 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | 3 | 29 | 41 | 64 | 116 | 251 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 23 | 44 | 120 | 1 | 67 | 238 |
| Neoplasms | D009369 | — | C80 | 31 | 24 | 62 | 5 | 48 | 159 |
| Venous thromboembolism | D054556 | EFO_0004286 | I74 | 10 | 32 | 50 | 17 | 37 | 141 |
| Venous thrombosis | D020246 | HP_0004936 | I82.40 | 5 | 16 | 39 | 15 | 28 | 97 |
| Lymphoma | D008223 | — | C85.9 | 21 | 40 | 17 | 1 | 13 | 86 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 16 | 24 | 22 | 1 | 15 | 69 |
| Covid-19 | D000086382 | — | U07.1 | 3 | 14 | 32 | 6 | 19 | 66 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 10 | 18 | 12 | 20 | 56 |
| Pulmonary embolism | D011655 | HP_0002204 | I26 | 4 | 5 | 21 | 10 | 19 | 56 |
Show 133 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 16 | 60 | 77 | — | 22 | 159 |
| Healthy volunteers/patients | — | — | — | 112 | 5 | 4 | — | 9 | 130 |
| Melanoma | D008545 | — | — | 38 | 51 | 12 | — | 17 | 107 |
| Colorectal neoplasms | D015179 | — | — | 11 | 23 | 50 | — | 30 | 101 |
| Prostatic neoplasms | D011471 | — | C61 | 8 | 11 | 41 | — | 25 | 84 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 19 | 22 | 28 | — | 14 | 76 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 13 | 25 | 19 | — | 23 | 70 |
| Head and neck neoplasms | D006258 | — | — | 3 | 21 | 22 | — | 13 | 57 |
| Leukemia | D007938 | — | C95 | 13 | 18 | 17 | — | 9 | 54 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 2 | 19 | 17 | — | 10 | 46 |
Show 509 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anus neoplasms | D001005 | EFO_0003835 | C21 | 1 | 1 | — | — | 3 | 5 |
| Hematologic neoplasms | D019337 | — | — | 2 | 3 | — | — | 1 | 5 |
| Anxiety | D001007 | EFO_0005230 | F41.1 | 1 | 1 | — | — | 4 | 5 |
| Myelodysplastic-myeloproliferative diseases | D054437 | — | — | 1 | 3 | — | — | 1 | 5 |
| Dentin sensitivity | D003807 | — | — | — | 1 | — | — | 4 | 5 |
| Brenner tumor | D001948 | — | — | 1 | 1 | — | — | 2 | 4 |
| Cystadenocarcinoma | D003536 | — | — | 1 | 1 | — | — | 2 | 4 |
| Verrucous carcinoma | D018289 | — | — | 1 | 3 | — | — | 1 | 4 |
| Primary myelofibrosis | D055728 | — | D47.4 | 1 | 1 | — | — | 1 | 3 |
| Chest pain | D002637 | HP_0100749 | R07.9 | — | 1 | — | — | 2 | 3 |
Show 72 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | 1 | — | — | — | 6 | 7 |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | 1 | — | — | — | 4 | 5 |
| Therapeutic equivalency | D013810 | — | — | 4 | — | — | — | — | 4 |
| Hepatic insufficiency | D048550 | — | — | 3 | — | — | — | 1 | 4 |
| Disease | D004194 | EFO_0000408 | R69 | 1 | — | — | — | 3 | 4 |
| Metabolic diseases | D008659 | EFO_0000589 | E88.9 | 1 | — | — | — | 3 | 4 |
| Coagulation protein disorders | D020147 | — | — | 1 | — | — | — | 2 | 3 |
| Drug interactions | D004347 | — | — | 3 | — | — | — | — | 3 |
| Systolic heart failure | D054143 | EFO_1001207 | I50.20 | 1 | — | — | — | 2 | 3 |
| Myelomonocytic leukemia juvenile | D054429 | — | C93.3 | 1 | — | — | — | 1 | 2 |
Show 17 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cerebral palsy | D002547 | — | G80 | — | — | — | — | 10 | 10 |
| Premature birth | D047928 | EFO_0003917 | O60 | — | — | — | — | 6 | 6 |
| Neck pain | D019547 | HP_0030833 | M54.2 | — | — | — | — | 6 | 6 |
| Sedentary behavior | D057185 | — | — | — | — | — | — | 6 | 6 |
| Exercise | D015444 | EFO_0000483 | — | — | — | — | — | 5 | 5 |
| Pressure ulcer | D003668 | — | L89 | — | — | — | — | 5 | 5 |
| Ataxia | D001259 | — | R27.0 | — | — | — | — | 4 | 4 |
| Insulin resistance | D007333 | HP_0000855 | E88.819 | — | — | — | — | 4 | 4 |
| Parenting | D016487 | — | — | — | — | — | — | 4 | 4 |
| Spinal muscular atrophy | D009134 | EFO_0003823 | G12.1 | — | — | — | — | 3 | 3 |
Show 344 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Antithrombin iii human |
| INN | antithrombin iii |
| Description | Thrombate III (antithrombin iii human) is an protein pharmaceutical. It is a concentrate of human antithrombin (AT) in lyophilized powder form for reconstitution for intravenous injection. |
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2108574 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | T0LTO7L82X (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 43,046 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
105 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use